Computational Biology and Bioinformatics (CBB) Track

Dr. Brandt completed a general Preventive Medicine residency at Madigan Army Medical Center in 1989 and a post-doctoral fellowship sponsored by the National Library of Medicine at Yale School of Medicine in 1997. She is board certified in Preventive Medicine and Clinical Informatics. Her research is interdisciplinary and focuses on issues related to the design, development and use of informatics tools in the domain of clinical research, as well as health services research.

After graduating from Harvard with a A.B. in physics in 1989, Prof. Mark Gerstein earned a doctorate in theoretical chemistry and biophysics from Cambridge University in 1993. He did postdoctoral research in bioinformatics at Stanford University from 1993 to 1996. He came to Yale in 1997 as an assistant professor in the Department of Molecular Biophysics and Biochemistry, and since 1999, in the Computer Science Department. He was named an associate professor in 2001, and the following year became co-director of the Yale Computational Biology and Bioinformatics Program. Gerstein has published appreciably in the scientific literature, with >400 publications in total, including a number of them in prominent venues, such as Science, Nature, and Scientific American. His research is focused on bioinformatics, and he is particularly interested in data science & data mining, macromolecular geometry & simulation, human genome annotation & disease genomics, and genomic privacy. 

Prof. O'Hern is a Professor of Mechanical Engineering & Materials Science and Physics, co-founder of the Integrated Graduate Program in Physical and Engineering Biology, and Director of Undergraduate Programs for the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences. His research employs theoretical and computational methods (e.g. all-atom and coarse-grained molecular dynamics simulations) to tackle a broad range of fundamental questions in soft matter and biological physics. Current projects include the dynamics of protein folding, unfolding, and
aggregation, the binding and self-assembly of proteins, and the structural
and mechanical properties of cells and tissues in the context of collective cell motion and wound healing.

Dr. Hongyu Zhao is the Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Data Science and Genetics, Chair of the Biostatistics Department and the Co-Director of Graduate Studies of the Inter-Departmental Program in Computational Biology and Bioinformatics at Yale University. He received his B.S. in Probability and Statistics from Peking University in 1990 and Ph.D. in Statistics from the University of California at Berkeley in 1995. His research interests are the developments and applications of novel statistical methods to address scientific questions in genetics, molecular biology, drug developments, and precision medicine.

Some of his recent projects include large scale genome wide studies to identify genetic variants underlying complex diseases, genetic risk prediction, single cell analysis, biological network modeling and analysis, disease biomarker identification, genome annotation, cancer genomics, microbiome analysis, and image analysis. He has published over 580 articles in statistics, human genetics, bioinformatics, and proteomics, and edited two books on human genetics analysis and statistical genomics. He has trained over 80 doctoral and post-doctoral students, many of whom are holding tenured or tenure-track positions at major universities in the states and overseas.

Dr. Zhao was a Co-Editor of the Journal of the American Statistical Association Theory and Methods, and has served on the editorial boards of several leading statistical and genetics journals. He was the recipient of the Mortimer Spiegelman Award for a top statistician in health statistics under the age of 40 awarded by the American Public Health Association and the Pao-Lu Hsu Award from the International Chinese Statistical Association. His research has also been recognized by the Evelyn Fix Memorial Medal and Citation by UC Berkeley, a Basil O'Connor Starter Scholar Award by the March of Dimes Foundation, election to the fellowship of the American Association for the Advancement of Science, the American Statistical Association, the Institute of Mathematical Statistics, and Connecticut Academy of Science and Engineering.

Julien Berro was initially trained in Applied Mathematics, Physics and Computer Sciences at the Institut National Polytechnique of Grenoble, France. He obtained his Ph.D. in Mathematical Modeling in Biology at Université Joseph Fourier, Grenoble, France, where he worked with Jean-Louis Martiel and Laurent Blanchoin on mathematical models for actin filament biochemistry and mechanics. After a brief tenure as an assistant professor in the department of Mathematics at Université Claude Bernard, Lyon, France, he decided to further his training by learning cell biology and quantitative microscopy in the laboratory of Tom Pollard at Yale University. Since he started his own laboratory in 2013, he has combined experimental, computational, and theoretical approaches to uncover the mechanisms of molecular machineries that produce forces in the cell, with a particular focus on the actin cytoskeleton and endocytosis.

Marcus Bosenberg M.D., Ph.D., is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Genomics, Genetics and Epigenetics Program of the Yale Cancer Center, Director of the Yale SPORE in Skin Cancer, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.

In his research, Dr. Bosenberg studies the genetics and cellular changes that result in melanoma, the leading cause of skin cancer deaths. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new melanoma therapies, and how the immune system can be stimulated to fight melanoma. He works to translate basic scientific findings into improvements in melanoma diagnosis and therapy. He has published over 100 peer-reviewed articles, is a member of the Yale Cancer Center Executive Committee, and is a faculty member of the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences.

Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Dr. Brandt completed a general Preventive Medicine residency at Madigan Army Medical Center in 1989 and a post-doctoral fellowship sponsored by the National Library of Medicine at Yale School of Medicine in 1997. She is board certified in Preventive Medicine and Clinical Informatics. Her research is interdisciplinary and focuses on issues related to the design, development and use of informatics tools in the domain of clinical research, as well as health services research.

Kei-Hoi Cheung, PhD has distinguished himself as a researcher and educator in the field of Biomedical Informatics with a growing national and international reputation. A particular strength is Dr. Cheung’s ability to forge strong, productive collaborations with a range of different bioscience researchers at Yale, in which his contributions include the development of complex databases and informatics tools that are critical for the research projects being performed. In the context of these collaborations, Dr. Cheung is simultaneously able to carry out his own informatics research on issues involved in robust interoperation and integration of databases and tools in the biosciences. In addition to giving talks and presentations at national and international meetings, he has published his own informatics research in peer-reviewed journals and conference proceedings, as well as contributing to publications focused on his collaborators’ research. He has established a broad base of collaborations with faculty in different departments at Yale, including Genetics, Pathology, Computer Science, Biostatistics, Molecular Biophysics and Biochemistry, and Biology. He was Director of Biostatistics and Bioinformatics Core of the NIDA Proteomics Center, focused on collaborative informatics support of neuroproteomics research at Yale. In addition to being a collaborator on numerous grants, Dr. Cheung has been PI on several federal grants (NIH and NSF). Dr. Cheung is also a core faculty member of Yale's Ph.D. Program in Computational Biology and Bioinformatics.

Dr. Cheung’ s research interests include the semantic web using the next generation of web technologies to integrate life science data and tools, and is co-editor of two books for Springer-Verlag titled: “Semantic Web: Revolutionizing Knowledge Discovery in the Life Sciences” and “Semantic e-Science”, respectively. Dr. Cheung also led the BioRDF task force (2008-2010) of the Semantic Web for Health Care and Life Sciences Interest Group that is an international community engaging in the creative use of Semantic Web in biomedicine. In addition, Dr. Cheung has recently embarked on natural language processing (NLP) projects in annotating, extracting and retrieving information from clinical text as part of the Veteran Administration (VA) electronic medical records. In summary, Dr. Cheung’s biomedical informatics expertise in database/semantic web research and NLP tool development, his national and international recognition as a researcher/educator, and his research contributions in these areas exemplify the attributes of a prominent researcher in biomedical informatics.

Coifman is a member of the American Academy of Arts and Sciences, the
Connecticut Academy of Science and Engineering, and the National Academy
of Sciences. He is a recipient of the 1996 DARPA Sustained Excellence
Award, the 1996 Connecticut Science Medal, the 1999 Pioneer Award of the
International Society for Industrial and Applied Science, and the 1999
National Medal of Science .

My lab focuses on understanding the biological processes driving immune and neurological diseases, with a particular interest in sex biases in these diseases. We use an integrative approach incorporating both wet and dry techniques, from large-scale genetic studies to detailed genomic dissections of cellular responses. For more information please see our lab website.

Forrest Crawford's work focuses on mathematical and statistical problems related to discrete structures and stochastic processes in epidemiology, public health, biomedicine, and evolutionary science.

Prof. Dellaporta studied at the University of Rhode Island (1972-76), Iowa State University (1976-78) and at the Worcester Polytechnic Institute (1978-81). His postdoctoral studies in plant molecular genetics were conducted at the Cold Spring Harbor Laboratory (1981-83). He has held positions of Staff Scientist at Cold Spring Harbor (1983-86), Assistant (1986-89), Associate (1990-96) and Full Professor (1996-present) in the Department of Molecular, Cellular and Developmental Biology at Yale University. His research program has focused on the genomic and computational biology of agronomic traits in crops such as of maize, rice and other cereals, including contributions to the identification and utility of of genetic diversity. He has co-authored numerous publications in scientific journals such as Cell, Nature, Science, Proc. Natl. Acad. Sciences, and Genetics, among others, and has served on the scientific advisory panels at the National Institute of Health, the National Science Foundation and the United States Department of Agriculture. Dr. Dellaporta has served a member of the Board of Control of the Connecticut Agricultural Experiment Station.

Dr. Flavell is Sterling Professor of Immunobiology at Yale University School of Medicine, and an Investigator of the Howard Hughes Medical Institute. He received his B.Sc. (Honors) in 1967 and Ph.D. in 1970 in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam (1970-72) with Piet Borst and in Zurich (1972-73) with Charles Weissmann. Before accepting his current position in 1988, Dr. Flavell was first Assistant Professor (equivalent) at the University of Amsterdam (1974-79); then Head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and subsequently President and Chief Scientific Officer of Biogen Research Corporation, Cambridge, Massachusetts (1982-88). Dr. Flavell is a fellow of the Royal Society, a member of the National Academy of Sciences as well as the National Academy of Medicine. Richard Flavell uses transgenic and gene-targeted mice to study Innate and Adaptive immunity, T cell tolerance and activation in immunity and autoimmunity,apoptosis, and regulation of T cell differentiation.

Samah Fodeh-Jarad, PhD is an Assistant Professor in the Department of Emergency Medicine, with a secondary appointment in the Yale School of Public Health. Dr. Fodeh has distinguished herself as researcher in the field of Biomedical Informatics and Big Data Science with a growing national and international reputation. Her contributions include the development of complex computational methods and tools that are critical for advancing biomedical informatics research and data science. Through her work, Dr. Fodeh demonstrates the utility of exploiting and combining multiple data modalities by employing methods from data mining and machine learning. One example is her research on mining social media and health care data to learn more about suicide risk and opioid addiction. Dr. Fodeh is also interested in assessing the impact of digital communications between patients and healthcare providers on several health-related outcomes. 

Joel Gelernter, MD, is Foundations Fund Professor of Psychiatry and Professor of Genetics and Neurobiology; and Director, Division of Human Genetics (Psychiatry), at the Yale University School of Medicine.

The research focus of his laboratory is genetics of psychiatric illness – phenotypes including cocaine, opioid, nicotine, cannabis, and alcohol dependence, posttraumatic stress disorder (PTSD), and panic and other anxiety disorders. He also studies a range of intermediate phenotypes, such as neuroimaging measures; and basic issues in population and complex trait genetics. The overall approach involves study of genetic polymorphism and sequence variation, on a molecular level and from the perspective of population genetics. Dr Gelernter’s laboratory published genomewide association studies (GWAS) for cocaine and opioid dependence, PTSD, alcohol dependence, nicotine dependence, and several related traits. All of these studies have resulted in the identification of novel risk loci.

After graduating from Harvard with a A.B. in physics in 1989, Prof. Mark Gerstein earned a doctorate in theoretical chemistry and biophysics from Cambridge University in 1993. He did postdoctoral research in bioinformatics at Stanford University from 1993 to 1996. He came to Yale in 1997 as an assistant professor in the Department of Molecular Biophysics and Biochemistry, and since 1999, in the Computer Science Department. He was named an associate professor in 2001, and the following year became co-director of the Yale Computational Biology and Bioinformatics Program. Gerstein has published appreciably in the scientific literature, with >400 publications in total, including a number of them in prominent venues, such as Science, Nature, and Scientific American. His research is focused on bioinformatics, and he is particularly interested in data science & data mining, macromolecular geometry & simulation, human genome annotation & disease genomics, and genomic privacy. 

Antonio studied Chemistry and Molecular Biology at the University of Cadiz and the University Autonoma of Madrid. During undergraduate, he worked with Gines Morata at the CBM in Madrid. Antonio did his PhD with Stephen Cohen at the EMBL (Heidelberg) (1998-2002) and a post-doc with Alex Schier at the Skirball Institute (NYU) and Harvard (2003-2006). Antonio established his laboratory at Yale in 2007 where he investigates the regulatory codes that shape gene expression during embryonic development. He was Director of Graduate Studies (2012-2016) and is currently Chair of the Genetics Department (2017- ).

Dr. Gruen received his BS and his MD degrees from Tulane University in New Orleans. He has been at Yale since beginning internship training in pediatrics in 1981, which was followed by subspecialty training in neonatology and research training in molecular genetics with Dr. Sherman Weissman. Dr. Gruen formally joined the faculty at Yale in 1988, splitting his time as a neonatology attending in the Newborn Intensive Care Unit (NICU) at Yale-New Haven Hospital and his lab where he initially mapped the gene for hemochromatosis. By 2000, the focus of his lab turned to mapping and identifying the reading disability (dyslexia) gene locus on chromosome 6 (DYX2). His lab was the first to generate high-resolution genetic markers, genetic association maps, and gene expression maps of DYX2. These studies led to the identification of DCDC2, a dyslexia gene that was cited by the journal Science as the 5th top breakthrough of 2005. The lab performed an NIH funded clinical study of DCDC2 and other genes related to reading and language in the ALSPAC birth cohort of 10,000 children and mothers. These studies identified the transcriptional control element called READ1, and READ1 alleles that are detrimental and protective for reading disability and language impairment. Dr. Gruen is the principal investigator for the Yale Genes, Reading and Dyslexia (GRaD) Study, a ground-breaking case-control study of dyslexia in 1,400 Hispanic American and African American children recruited from seven sites across North America. He was the Yale site PI for the NIH Pediatric Imaging NeuroGenetics (PING) Data Resource Study of 1,575 normal children, ages 3-20 years. Most recently, Dr. Gruen started the New Haven Lexinome Project, a new six-year longitudinal study of the genetics of response-to-intervention spanning the entire 2015 and 2016 New Haven Public Schools first grade classes. The goals of the New Haven Lexinome Project are to determine risk for learning disabilities conferred by specific genetic variants for presymptomatic diagnosis, and to determine how genetic variants inform intervention for precision/personal education. In addition to his research, Dr. Gruen continues to attend 8 weeks each year in the NICU at the Children’s Hospital at Yale-New Haven.

How genes can change language. Short video showing how our genes could account for a substantial amount of the diversity of languages around the world

How genes can change language. Short video showing how our genes could account for a substantial amount of the diversity of languages around the world

Dr. Murat Gunel, Professor of Neurosurgery, assumed the position of chief of Neurovascular Surgery Program in January of 2001. Dr. Gunel is a board certified neurosurgeon and is a fellow of the American College of Surgeons. He has special interest in treating brain aneurysms and vascular malformations with special emphasis on arterio-venous malformations and cavernous malformations. He also has expertise in occlusive vascular disorders such as carotid disease and gamma knife surgery (radiosurgery).

His laboratory interests parallel his expertise in clinical neurovascular surgery and focus on gene discovery in disorders of the nervous system and its vasculature. Dr. Gunel's lab completed the two largest genome wide association studies (GWAS) aimed at understanding common variants that underlie intracranial aneurysm genetic risk based on the analysis of over 20,000 subjects. In addition, he is interested in the identification of genes important in human brain development through the study of rare, consanguineous families with recessive forms of malformations of cortical development.

Dr. Hall's research career spans the fields of genetics, genomics, bioinformatics and data science. He received a B.A. in Integrative Biology from the University of California at Berkeley (1998), and worked as a technician for 2 years in Sarah Hake's plant genetics group at the USDA/ARS Plant Gene Expression Center. He received his Ph.D. in genetics from Cold Spring Harbor Laboratory (2003), where his work in Shiv Grewal's laboratory established the first direct link between RNA interference and chromatin-based epigenetic inheritance. As a postdoc with Michael Wigler (2004) and independent Cold Spring Harbor Laboratory Fellow (2004-2007), Dr. Hall used microarray technologies and mouse strain genealogies to conduct the first systematic study of DNA copy number variation hotspots. As a faculty member at the University of Virginia (2007-2014), Washington University (2014-2020) and Yale (2020-present), his work has sought to understand the causes and consequences of genome variation in mammals, with an increasing focus on computational methods development and human genetics. His group has developed bioinformatics tools for variant detection, variant interpretation, sequence alignment, data processing, and data integration. He has led genome-wide studies of human genome variation, heritable gene expression variation, human genetic disorders, tumor evolution, mouse strain variation, genome stability in reprogrammed stem cells, and single-neuron somatic mosaicism in the human brain. Dr. Hall's work has been featured in Science Magazine's Breakthrough of the Year (2003 & 2007), the NIMH Director's "Ten Best of 2013" and The Scientist (2013), and he has received several prestigious awards including the AAAS Newcomb Cleveland Prize (2003), the Burroughs Wellcome Fund Career Award (2006), the NIH Director's New Innovator Award (2009), and the March of Dimes Basil O'Connor Research Award (2010). He has also served as an Associate Editor at Genome Research (2009-2014) and Genes, Genomes and Genetics (2011-2018).

Most recently, Dr. Hall has played a leadership role in several large collaborative projects funded by NIH/NHGRI including the Centers for Common Disease Genomics, the AnVIL cloud-based data repository and analysis platform, and the Human Pangenome Project. His current work is focused on two broad goals: (1) mapping variants and genes that confer risk to human disease, with ongoing projects focused on coronary artery disease and cardiometabolic traits in unique and underrepresented populations, and (2) developing methods for the detection and interpretation of human genome variation, with an emphasis on structural variation and other difficult-to-detect forms, and on comprehensive trait association in human disease studies.

Dr. Justice is a Clinical Epidemiologist who has developed multiple large national cohorts based on data from the Veterans Affairs Healthcare System Electronic Medical Record enhanced with National Death Index and CMS data, patient completed surveys, DNA and tissue repositories, and stored pathology samples. She has two decades of experience in the processes required to clean, validate, and standardize raw EMR data and in its analysis using standard statistical methods, machine learning techniques, and cross cohort validations. The oldest and best known of her projects is the Veterans Aging Cohort Study (VACS). VACS is an ongoing, longitudinal study of >170,000 United States veterans with and without HIV infection continuously funded by National Institutes of Health (NIH) since 1996. She has developed and validated widely used indices including a prognostic index, the VACS Index, and a patient reported symptom index, the HIV Symptom Index. She is the principal investigator of the National Cancer Institute provocative questions grant HIV and Aging Mechanisms for Hepatocellular Cancer, has published over 400 peer reviewed manuscripts, and has presented work at the United Nations, The International AIDS Society, The Royal Medical College in London, the White House, and Congress. She is a member of the National Cancer Institute Ad hoc Subcommittee on HIV and AIDS Malignancy and the HIV and Aging Working Group, NIH Office of AIDS Research. She has recently joined the International Advisory Boards of Lancet HIV and Journal of the International AIDS Society.  

Dr. Naftali Kaminski is, as of July 1st, 2013, the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine. Before that he was a tenured professor of Medicine, Pathology, Computational Biology and Human Genetics, and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research at the University of Pittsburgh. Dr. Kaminski was the director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease and the Lung, Blood and Vascular Center for Genomic Medicine at the division of Pulmonary, Allergy and Critical Care Medicine in University of Pittsburgh. Dr Kaminski received his medical degree from the Hebrew University - Hadassah Medical School in Jerusalem, Israel, and completed a residency in Internal Medicine at Hadassah Mount-Scopus University Hospital in Jerusalem, and a fellowship in pulmonary medicine at Sheba Medical Center in Tel-Hashomer, Israel. Dr Kaminski received his basic science training in Dean Sheppard's laboratory at the Lung Biology Center at UCSF and in functional genomics and microarray technology at the Functional Genomics laboratory at Roche Bioscience, Palo-Alto. After his fellowship in 2000, Dr. Kaminski was appointed head of Functional Genomics at Sheba Medical Center in Israel, before being recruited to head the Simmons Center at the University of Pittsburgh in 2002.

Dr. Kaminski's main research interests involve applying genomic approaches to elucidate basic mechanisms and improve diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic mostly lethal and currently untreatable scarring lung disease and other chronic lung diseases such Chronic Obstructive Pulmonary Disease (COPD), severe asthma and sarcoidosis. His group pioneered the application of high throughput genome scale transcript profiling in advanced lung disease. Among his key scientific achievements are: The discovery of novel molecules  with significant active roles in pulmonary fibrosis, including matrix metalloproteases (MMP7, MMP19) and phosphatases (SHP2, MKP5) , demonstrating that microRNAs, a family of small non-coding RNAs, are differentially expressed in IPF, and that some of them (let-7, mir-29, mir-33) are mechanistically involved in lung fibrosis, and the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr. Kaminski's team identified a potential antifibrotic role for thyroid hormone signaling, a novel discovery with significant therapeutic implications, and performed single cell RNA sequencing on >300,000 cells obtained from patients with advanced lung disease and created an online freely available data dissemination tool (www.IPFCellAtlas.com). Dr. Kaminski has a strong interest in integrating high throughput ‘omics’ data, such as genome scale DNA variants, coding and non-coding RNAs, microbiome and metabolome information with clinical information to generate systems biology models of lung diseases and to develop precision medicine approaches that are significantly more precise, predictive and patient centered than anything that is currently available.

Since completing his clinical training, Dr. Kaminski authored more than 275 research papers, review articles and book chapters and has given numerous invited talks at national and International conferences. Since he finished his fellowship in 2000, Dr. Kaminski has been consistently funded by NIH and is the PI of multiple NIH grants. Dr. Kaminski was a recipient of the Marvin I. Schwarz Award for contributions to patient care and research in pulmonary fibrosis from the Coalition for Pulmonary Fibrosis in 2010 and the University of Pittsburgh Innovator Award in 2012. In 2013, Dr. Kaminski received the American Thoracic Society Recognition of Scientific Achievements award, as well the Helmholtz Institute International Fellow. In 2015 he was elected to the Association of American Physicians. In 2016 he was elected as Fellow of the European Respiratory Society (ERS) , and won the the European Respiratory Society Gold medal for Interstitial Lung Disease. In 2018, Dr. Kaminski received the Andy Tager Excellence in Mentorship Award from the Respiratory Cell and Molecular Biology Assembly of the American Thoracic Society and was elected fellow  of the American Thoracic Society. Dr. Kaminski is active on the ATS and was the editor of “Gene Express”, a column on genomics in the initial days of the ATS Website, a member and chair of the Program Committee of the Assembly on Respiratory Cell and Molecular Biology of the ATS, and member of the ATS Research Advocacy Committee, and Chair of the Assembly on Respiratory, Cell, and Molecular Biology at the American Thoracic Society. He was an associate editor of the American Journal of Respiratory and Critical care Medicine, a member of multiple editorial boards and recently the Deputy Editor of Thorax, BMJ. Dr. Kaminski served as the President of the Association of Pulmonary, Critical Care and Sleep Division Directors in 2019.

Dr. Kaminski is passionate about training physician scientists for the challenges of 21st century medicine, and especially in the vocabulary, skills and technology of the new fields of genomics, bioinformatics, computational and system biology and their application to understanding the basic mechanisms that govern lung health and disease as well as to designed personalized medicine approaches and has mentored multiple MD and PhD scientists, of them many have productive and well funded independent career. He has most recently recognized for his commitment to mentoring with the American Thoracic Society Andy Tager excellence in mentoring award.

Dr. Steven Kleinstein is a computational immunologist with a combination of "big data" analysis and immunology domain expertise. His research interests include both developing new computational methods and applying these methods to study human immune responses. Dr. Kleinstein received a B.A.S. in Computer Science from the University of Pennsylvania and a Ph.D. in Computer Science from Princeton University. He is currently Professor of Pathology (with a secondary appointment in Immunobiology) at the Yale School of Medicine, and a member of the Interdepartmental Program in Computational Biology and Bioinformatics (CBB), and the Human and Translational Immunology Program. 

Specific areas of research focus include:

• High-throughput B cell receptor (BCR) repertoire profiling (AIRR-seq or Rep-seq)
• Immune signatures of human infection and vaccination responses